Neil Singla, Chief Medical Officer of Latigo Biotherapeutics, Inc., reported the acquisition of 350,000 employee stock options on November 15, 2026, in a statement of changes in beneficial ownership filed with the SEC on November 18, 2026.

Key Highlights

  • Reporting person: Neil Singla, Chief Medical Officer of Latigo Biotherapeutics, Inc. (NASDAQ:LTGO)
  • Security awarded: Employee Stock Option (right to buy) covering 350,000 shares of Common Stock
  • Exercise price: $13.11 per share
  • Transaction date: November 15, 2026, with an expiration date of November 14, 2036
  • Acquisition price: $0 per the filing, with the option acquired directly by the reporting person
  • Vesting schedule: 25% vests March 31, 2027; 25% vests November 3, 2027; 50% vests May 3, 2028
  • Beneficial ownership following transaction: 350,000 derivative securities, held directly

Neil Singla's Stock Option Grant at Latigo Biotherapeutics

According to the filing, Neil Singla, who serves as Chief Medical Officer of Latigo Biotherapeutics, Inc., received a grant of 350,000 employee stock options on November 15, 2026. The options carry an exercise price of $13.11 per share and are exercisable on Common Stock of the company. The filing records the acquisition price of the derivative security as $0, and Singla holds the options directly. The option term runs through November 14, 2036, giving a ten-year window from the grant date.

The filing discloses a multi-tranche vesting schedule tied to specific calendar dates rather than a standard cliff or uniform monthly schedule. Per the explanation of responses in the filing: "25% of the total shares subject to this option shall vest on March 31, 2027, 25% of the total shares subject to this option shall vest on November 3, 2027, and 50% of the total shares subject to this option shall vest on May 3, 2028." This means the final tranche, representing 175,000 shares, does not vest until May 3, 2028. Latigo Biotherapeutics is a biotherapeutics company, with its registered address listed in the filing as 1300 Rancho Conejo Blvd., Suite 305, Thousand Oaks, California 91320.

The filing was signed by Sabrina Nieder as Attorney-in-Fact on November 18, 2026, and indicates this was filed by one reporting person. No non-derivative securities transactions were reported in Table I of the filing. Prior to this grant, the filing reflects no pre-existing derivative security holdings for Singla; following the transaction, his total beneficial ownership of derivative securities stands at 350,000 options, all held directly.

What Was Disclosed

Latigo Biotherapeutics' Chief Medical Officer Neil Singla reported the acquisition of 350,000 employee stock options at an exercise price of $13.11, granted November 15, 2026, with a structured three-tranche vesting schedule concluding May 3, 2028, and expiring November 14, 2036.